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Abstract
Diagnosis of the neglected tropical disease, Buruli ulcer, can be made by acid-fast smear microscopy, specimen culture on
mycobacterial growth media, polymerase chain reaction (PCR), and/or histopathology. All have drawbacks, including non-
specificity and requirements for prolonged culture at 32uC, relatively sophisticated laboratory facilities, and expertise,
respectively. The causative organism, Mycobacterium ulcerans, produces a unique toxin, mycolactone A/B (ML) that can be
detected by thin layer chromatography (TLC) or mass spectrometric analysis. Detection by the latter technique requires
sophisticated facilities. TLC is relatively simple but can be complicated by the presence of other lipids in the specimen. A
method using a boronate-assisted fluorogenic chemosensor in TLC can overcome this challenge by selectively detecting ML
when visualized with UV light. This report describes modifications in the fluorescent TLC (F-TLC) procedure and its
application to the mouse footpad model of M. ulcerans disease to determine the kinetics of mycolactone production and its
correlation with footpad swelling and the number of colony forming units in the footpad. The response of all three
parameters to treatment with the current standard regimen of rifampin (RIF) and streptomycin (STR) or a proposed oral
regimen of RIF and clarithromycin (CLR) was also assessed. ML was detectable before the onset of footpad swelling when
there were ,10
5 CFU per footpad. Swelling occurred when there were .10
5 CFU per footpad. Mycolactone concentrations
increased as swelling increased whereas CFU levels reached a plateau. Treatment with either RIF+STR or RIF+CLR resulted in
comparable reductions of mycolactone, footpad swelling, and CFU burden. Storage in absolute ethanol appears critical to
successful detection of ML in footpads and would be practical for storage of clinical samples. F-TLC may offer a new tool for
confirmation of suspected clinical lesions and be more specific than smear microscopy, much faster than culture, and
simpler than PCR.
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Introduction
Buruli ulcer, a neglected tropical disease caused by Mycobacterium
ulcerans, occurs in marshy environments in scattered countries
and regions on most of the world’s continents [1]. While its mode
of transmission remains uncertain, it is now known that the
principal virulence factor is a secreted cytotoxic lipid, mycolactone
[2], whose synthetic enzymes are encoded on a giant plasmid [3].
Both features are unique among mycobacteria. Until nearly 10
years ago, the only accepted mode of treating the disease was to
surgically remove the lesion and surrounding tissue followed by
skin grafting [1]. Using a mouse footpad model developed in
the 1950s [4] and applying the lessons of tuberculosis and leprosy
chemotherapy, combination regimens of antibiotics were tested
in the early 2000s [5–7]. The most effective treatment was found
to be a combination of rifampin (RIF), an oral drug used
for treatment of most mycobacterial infections, and streptomycin
(STR), an injectable drug originally used to treat tuberculosis.
Subsequent clinical studies [8–11] supported the efficacy of
this regimen and resulted in the replacement of surgery with
antimicrobial treatment in most programs around the world [1].
Different forms of mycolactone are produced by M. ulcerans in
different locales. They can be detected by mass spectrometry,
cytotoxicity assays, or thin-layer chromatography (TLC) [12–17].
The major mycolactone is mycolactone A/B[18]. Total synthesis of
the mycolactones was demonstrated [19,20] and synthetic myco-
lactone A/B has been made available for research purposes.
SeekingtoimprovetheTLCmethod byreducingbackgroundspots,
Spangenberg and Kishi [17] developed a boronate-assisted
fluorescent-TLC (F-TLC) method in which there is a marked
reduction of background spots. The TLC plate is developed by
immersion in a boronic acid acetone solution that binds to myco-
lactone and fluoresces on excitation by ultraviolet light. Interest-
ingly, this method is specific to detect human mycolactones, but not
fish or frog mycolactones, as well as some unknown contaminants.
Unpublished results indicated that synthetic mycolactone spiked
PLOS Neglected Tropical Diseases | www.plosntds.org 1 January 2014 | Volume 8 | Issue 1 | e2618into tissue could be detected by F-TLC but detection in clinical
samples was often problematic, probably due to the storage method
of samples. These results prompted further development and
refinement of the F-TLC assay, which is reported here.
The mouse footpad model has the advantage of a readily visible
and progressive swelling of the infected foot [1,5–7]. Harvested
footpads can also be processed for enumeration of M. ulcerans
colony forming units (CFU) by culture on mycobacterial media for
up to 12 weeks at 32uC. Previous studies documented histological
and microbiological changes after infection as well as changes in
toxin levels in frozen footpads before and after treatment with
RIF+STR [21–26]. Among the goals of the World Health
Organization Global Buruli Ulcer Initiative is to find an all-oral
regimen, in other words to replace STR with an oral alternative
such as clarithromycin (CLR) [27–29].
In the current study, we documented weekly changes in footpad
swelling, CFU counts, and toxin levels in infected mouse footpads
beforeandaftertreatment,comparingthe efficacyofRIF+STR and
RIF+CLR. After preliminary studies with convenience samples, we
were able to show that mycolactone may be best preserved not by
freezing but by storage in absolute ethanol, a finding that could also
be of practical benefit under field conditions.
Materials and Methods
Bacteria
M. ulcerans 1615 (Mu1615), an isolate originally obtained from a
patient in Malaysia in the 1960s [30], was kindly provided by Dr.
Pamela Small, University of Tennessee. According to Dr. Small
(personal communication), this strain is a stable producer of
mycolactone A/B whereas modern African strains often lose the
capacity to produce mycolactone unless passaged in mice (Drs.
Stewart Cole and Laurent Marsollier, personal communication
to JHG). Previous studies have confirmed that this strain produces
mycolactone A/B and kills macrophages and fibroblasts [24,
31,32]. The strain was passaged in mouse footpads before use in
these studies. The bacilli were harvested from swollen footpads at
the grade 2 level, i.e., swelling with inflammation of the footpad
[6].
Ethics statement
All animal procedures were conducted according to relevant
national and international guidelines. The study was conducted
adhering to the Johns Hopkins University guidelines for animal
husbandry and was approved by the Johns Hopkins Animal Care
and Use Committee, protocol MO11M240. The Johns Hopkins
program is in compliance with the Animal Welfare Act regulations
and Public Health Service (PHS) Policy and also maintains
accreditation of its program by the private Association for the
Assessment and Accreditation of Laboratory Animal Care (AAA-
LAC) International.
Antibiotics
RIF and STR were purchased from Sigma (St. Louis, MO).
CLR was kindly provided by Abbott (Abbott Park, IL). STR and
RIF were dissolved in distilled water, and CLR was dissolved in
distilled water with 0.05% agarose for administration to mice. All
drugs were administered 5 days per week in 0.2 ml. RIF (10 mg/
kg) and CLR (100 mg/kg) were administered by gavage. STR
(150 mg/kg) was administered by subcutaneous injection.
Infection and CFU analysis
BALB/c mice, age 4–6 weeks (Charles River, Wilmington,
MA), were inoculated in the right hind footpad with approxi-
mately 4.54 log10 (3.45610
4) CFU of Mu1615 in 0.03 ml PBS.
Footpads were harvested weekly from 8 mice (5 for CFU count, 3
for ML detection) at different time points after infection (Table 1)
and before treatment, up to $grade 3 swelling. After the onset of
grade 2 swelling (week 6), treatment with RIF+STR or CLR
was administered for 5 weeks (week 11 after infection). Groups of
treated mice were also sacrificed for these analyses. Footpad tissue
was harvested, minced with fine scissors, suspended in 2.5 ml PBS,
serially diluted, and plated on Middlebrook selective 7H11 plates
(Becton-Dickinson, Sparks, MD). Plates were incubated at 32uC
and colonies were counted after 10 weeks with a final determi-
nation at 12 weeks of incubation.
Analysis of mycolactone A/B
Tissue harvest. Footpads were harvested for detection of
mycolactone by stripping bottom and top sides of the infected and
contralateral footpads and then immediately immersing the two
sidesintoa polypropylene MicrewtubeH tubewith O-ringand screw
cap (Simport Scientific, Beloeil, QC, Canada) containing 750 ml
absolute ethanol. Preliminary experiments indicated that mycolac-
tone is stably preserved in ethanol for at least 3 weeks. Tubes were
wrapped and kept in the dark at room temperature. Samples were
usually shipped overnight to the Harvard lab within 24 hours and
on one occasion after 7 days for logistical reasons.
Tissue processing. The EtOH solvent was transferred to a
glass vial (VWR 66011-041) and evaporated. Footpad was weighed
(wet weights of footpads varied from ,50 mg (grade 1 infection) up
to 120 mg (grade 4 infection)), before transferring the tissue to a 7-
ml Dounce tissue grinder and homogenization in 1.0 mL ethyl
acetate (EtOAc). The homogenate was filtered through a Pasteur
pipette containing a cotton plug into the original glass vial that had
contained the EtOH solvent. The pestle was then rinsed with
,1.5 ml EtOAc and the solvent was again evaporated. After
evaporation, 50 ml of EtOAc was added to the vial and 35 ml was
spotted onto a 366 cm fluorescent-dye free TLC plate (TLC Silica
gel 60, EMD Millipore, Darmstadt, Germany; Gibbstown, NJ,
USA) along with spots for 5, 10, and 20 ng synthetic mycolactone
A/B standards. The plates were developed in 90:10:1 chloroform:-
methanol:water, air-dried, and dipped in boronic acid [17], heated
Author Summary
The diagnosis of Buruli ulcer, caused by infection with
Mycobacterium ulcerans, is complicated by its resemblance
to other diseases that may also cause ulcers in the skin.
Clinical diagnosis can be supported by microscopic detec-
tion of acid-fast bacilli in the skin, by prolonged culture of
at least 8 weeks, in a dedicated incubator set at 32uC, or by
the polymerase chain reaction in a well-equipped labora-
tory usually far from the clinic where the patient comes for
treatment. The treatment involves taking two drugs, one
requiring injections, every day for two months, a burden
for patients and their families. Since all drugs may have
side effects, it is important that the treatment be appro-
priate for the patient’s disease. We describe a new
technique to rapidly and inexpensively detect the pres-
ence of the unique toxin produced by M. ulcerans in the
mouse footpad model of Buruli ulcer. We show that the
toxin can be detected in footpads before the development
of signs of the disease, that more toxin is produced as the
disease progresses, and that toxin levels decline in mice
treated with either the current standard regimen of
rifampin and streptomycin or a proposed all-oral drug
regimen of rifampin and clarithromycin.
Fluorescent TLC for Mycolactone Detection
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acetone on a paper towel. The plate was placed on a UV lamp with
a 365 nm filter. Fluorescent spot intensity was compared to that of
the standards to estimate the amount of mycolactone A/B in the
sample. TLC photos were taken and subjected to resolution
enhancement(AdobePhotoshopCS6).TLC-picturesthusobtained
serve for recording purposes, although the sensitivity with eye-
analysis is better. For illustration, F-TLC pictures for Week 8 of
untreated and RS-treated (for 2 weeks) are shown in Figure 1.
As 70% of the EtOAc solution (35 ml out of 50 ml EtOAc) was
used for F-TLC analysis, an amount of mycolactone A/B present
in a footpad corresponds to (estimated amount from F-TLC)
ng6(50/35).
Statistical analysis
GraphPad Prism 4 was used to compare group means by
student’s T test and analysis of variance and linear regression
analysis for comparison of slopes and intercepts.
Results
Footpad swelling
The most rapid but least specific method of assessing M. ulcerans
infection in human disease is to check for typical lesions. In the
mouse model where infection time is known, the method is
straightforward and well documented [6,24,27,31]. Figure 2 shows
a detailed assessment of swelling progression with weekly obser-
vations. Swelling was suggested as early as 4 weeks after infection
with unambiguous enlargement (grade 160.25) of footpads at
week 5. The average footpad-swelling grade increased to level 2
(2.2560.66) at week 6 and increased again to grade 3 (3.1760.38)
at week 7. At week 8 when the average reached 3.560.00, mice
were sacrificed per protocol. The contralateral uninfected footpads
showed no indications of swelling throughout the experiment.
What was unknown in this time course was whether swelling is
preceded by the presence of detectable mycolactone or if the
number of organisms present in the footpad determines swelling.
Mycolactone production
In this experiment, footpads stored in absolute ethanol were
shipped overnight to the chemistry lab and quantitative mycolac-
tone A/B results were determined within 24–48 hours of footpad
harvest. As shown in Figure 3, mycolactone was detectable at
,11 ng (,7.5 ng650/35)/footpad at week 4, one week before the
observation of unambiguous footpad swelling. The amount
increased to 2662 ng ((1862 ng)650/35)/footpad at week 5,
3162 ng ((2262 ng)650/35) at week 6, the beginning of treat-
ment, 4062 ng ((2863 ng)650/35) at week 7, and 4964n g
((3463n g ) 650/35) at week 8 in untreated mice. These results
indicate that the mycolactone toxin is present in ‘‘pre-clinical’’
lesions and can be detected in footpad tissue extracts by fluorescent
TLC.
Table 1. Experimental scheme.
Week 0 1 2 3 4 5 6 6.1* 6.5{ 7891 0 1 1 T o t a l
CFU (no Rx) 555555 4 5 5 4 4
CFU RS 5555542 9
CFU RC 5555542 9
ML (no Rx) 3 3 3 3 3 3 3 3333333 9
M L R S 3 3333332 1
M L R C 3 3333332 1
Total 8 8 8 8 8 8 9 23 24 24 19 19 17 183
Mice were randomized after infection with 0.03 ml of an inoculum containing 6.06 log10/ml;
Treatment with RS: RIF, 10 mg/kg, +STR, 150 mg/kg or RC: RIF, 10 mg/kg, +CLR, 100 mg/kg.
Treatment (Rx) start time was week 6 when mice had average swelling grade of 2 and continued for 5 weeks (i.e. week 11 after infection);
*Week 6+1 Day treatment;
{Week 6+3 Days treatment;
CFU counts done only on infected right hind footpad (RHFP);
ML=Mycolactone A/B detection experiments done on both footpads.
doi:10.1371/journal.pntd.0002618.t001
Figure 1. TLC-pictures for Week 8 of untreated and RS-treated
mice. TLC-photos were taken and subjected to resolution enhance-
ment (Adobe Photoshop CS 6). Panel A: untreated mouse. By visual
comparison with the controls, the amount of mycolactone A/B in the
right hind footpad (RHFP) sample was estimated to be 35–40 ng, which
corresponds to 50–57 ng per footpad. No mycolactone A/B was
detected in the left hind footpad (LHFP). Panel B: RS-treated (for 2
weeks) mouse. By visual comparison with the controls, the amount of
mycolactone A/B in the RHFP sample was estimated to be 15–20 ng,
which corresponds to 21–28 ng per footpad. No mycolactone A/B was
detected in the LHFP.
doi:10.1371/journal.pntd.0002618.g001
Fluorescent TLC for Mycolactone Detection
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Using quantitative culture at 32uC on selective Middlebrook
7H11plates,countablecolonieswerepresentonlyafter10weeks.At
baseline, on day 1 after infection the CFU counts were 3.4560.34
log10 per footpad. There was a gradual increase weekly with the
CFU burden being 3.6560.17, 4.2660.18, 4.5060.26, 4.9260.19,
and, at the time of detectable footpad swelling, just over 5 log10 at
5.2060.10 log10 per footpad at weeks 1, 2, 3, 4, and 5, respectively,
after infection (Figure 4). After initial footpad swelling, there was a
further increase in M. ulcerans CFU to 5.9660.26 log10 at which
point there was a plateau with counts at subsequent weeks (7 and 8)
being 6.1360.28 and 6.2360.41 log10/footpad, respectively.
However, swelling and mycolactone production continued to
increase. From these data, we conclude that footpad swelling only
occurs after there are approximately 5log10 organisms in the
footpad and that bacterial multiplication increases only slightly after
that time while footpad swelling increases dramatically.
Impact of RIF+STR and RIF+CLR treatment
Footpad swelling. On average, footpad swelling decreased
steadily after the onset of treatment (week 6) with either the current
standard regimen of RIF+STR or the proposed oral regimen of
RIF+CLR from an average of grade 2 to an average of less than
grade 1 asshown inFigure2.Treatment was foronly5 weeksrather
than the standard 8 weeks, which we have shown previously [24]
using RIF+STR to render all or nearly all mice free of detectable
footpad swelling. From these data, it would appear that the
RIF+CLRcombinationshouldbeequallyeffectiveastheRIF+STR
combination in eliminating apparent signs of disease.
Mycolactone production. Over the 5 weeks of treatment,
there was also a steady decrease in the production of detectable
mycolactone A/B by F-TLC, regardless of antimicrobial regimen.
This suggests that the drugs cripple mycolactone production either
by inhibiting the machinery of the M. ulcerans plasmid or by kill-
ing the organism. Levels declined from 2962 ng/footpad at the
beginning of treatment to less than 5 ng/footpad after 5 weeks of
treatment at week 11. Again, neither regimen displayed discernible
superiority on disabling the production of mycolactone A/B
(Figure 3).
M. ulcerans multiplication and survival. As shown pre-
viously [24,27], there is a rapid decrease in the number of M.
ulcerans CFU after the beginning of treatment with RIF+STR. The
decrease in this experiment was greater during the second week of
Figure 2. Footpad swelling in mice infected with M. ulcerans
before and after antibiotic treatment. After infection in the right
hind footpad (RHFP), grade 1 swelling was first detected at 5 weeks.
Treatment began when swelling averaged grade 2 at week 6. Swelling
continued to increase for the next two weeks to grade 3.5 in untreated
control mice (red squares). Swelling was arrested in mice treated with
either rifampin and streptomycin (RS, green circles) or rifampin and
clarithromycin (RC, blue triangles) and then declined at a comparable
rate to a grade of ,1 over the 5-week treatment period used in this
experiment. No swelling occurred in the uninfected contralateral left
hind footpads.
doi:10.1371/journal.pntd.0002618.g002
Figure 3. Detection of mycolactone A/B in footpads infected
with M. ulcerans before and after antibiotic treatment. After
infection with M. ulcerans in the right hind footpad (RHFP), ,11 ng
(,7.5 ng650/35) mycolactone A/B per footpad was detected at 4
weeks, one week before the observation of grade 1 swelling of the
footpads. Treatment began when swelling averaged grade 2 at week 6
and mycolactone A/B levels were at 3162 ng ((2262 ng)650/35) per
footpad. Mycolactone production continued to increase for the next
two weeks in untreated control mice (red squares), reaching 4964n g
((3463) ng650/35). Mycolactone production was arrested in mice
treated with either rifampin and streptomycin (RS, green circles) or
rifampin and clarithromycin (RC, blue triangles) and then declined to
near undetectable levels (,5 ng) over the 5-week treatment period
used in this experiment. At no time was mycolactone A/B detected in
the contralateral left hind footpads.
doi:10.1371/journal.pntd.0002618.g003
Figure 4. M. ulcerans CFU in mouse footpads before and after
antibiotic treatment. After infection in the right hind footpad (RHFP),
there were increases in the numbers of M. ulcerans detected in the
footpads. At week 4, the time of detectable mycolactone A/B, there
were 4.960.2 log10 CFU in the footpads and there were 5.260.1 log10
CFU at week 5, the time of observable footpad swelling. CFU levels
peaked at 6.260.4 log10, at week 8 in untreated mice, little changed
from the 6.060.3 log10 found at the beginning of treatment at week 6.
M. ulcerans growth was arrested in mice treated with either rifampin
and streptomycin (RS, green circles) or rifampin and clarithromycin (RC,
blue triangles). After 5 weeks of RS treatment, all footpads were culture
negative whereas 3/5 mice treated with RC were culture negative.
doi:10.1371/journal.pntd.0002618.g004
Fluorescent TLC for Mycolactone Detection
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treated mice and these mice were all culture negative by the
completion of 5 weeks of treatment (Figure 4). There was a parallel
decrease in the RIF+CLR-treated mice in which 3 of 5 mice were
culture negative by the completion of treatment. In summary,
although there was no significant difference between the slopes of
the curves of the two regimens as assessed by linear regression
analysis, the time to culture negativity at 10.5 weeks vs. 11.1 weeks
was statistically significantly earlier (p,0.025) in mice treated with
RIF+STR.
Discussion
The described developments in the fluorescent TLC procedure
for the detection of mycolactone A/B in mice infected with M.
ulcerans may have practical implications. This detection technique
for the unique toxin of M. ulcerans may enable simpler and earlier
specific diagnosis of Buruli ulcer in humans. Acid-fast microscopy
for detection of M. ulcerans is also relatively rapid but lacks both
sensitivity and specificity and histology requires expertise often not
present in endemic areas. Molecular tests can also be applied but
have similar limitations though PCR is relatively sensitive [33,34].
The most sensitive and specific method of detection is culture at
32uC on microbiological media but it requires up to 8 weeks for
detection and up to 12 weeks for quantification in this model
[24,33,35] and is prone to contamination. Here, detection of
mycolactone, a specific marker of M. ulcerans, was achieved within
days of tissue harvest and even before the presence of a lesion (i.e.,
footpad swelling) in the mouse model. Compared to our previous
studies [24] with frozen footpads and mycolactone detection by
mass spectrometry, storage in absolute ethanol appears to be the
key for detection at earlier phases of the infection and to increase
sensitivity of TLC. Ethanol is also a more practical option than
deep-freezing in the field. Experiments comparing ethanol with
iso-propanol and ethyl acetate as the storage medium indicated
that iso-propanol might be slightly superior to ethanol but that
ethanol is clearly superior to ethyl acetate (unpublished observa-
tions). The differences were principally in the degree of diffusion of
the spots. In footpads not kept in any of these solvents, there was
almost complete elimination of detectable mycolactone.
Wehavealsomorepreciselydetermined therelationship between
footpad swelling, toxin production, and bacterial multiplication.
Mycolactone A/B can be detected before the onset of footpad
swelling when there are ,10
5 bacilli per footpad and swelling
occurs when there are .10
5 bacilli in the footpad. As observed
previously [24], there is a plateau in bacillary numbers soon after
the onset of swelling, even though swelling continues to increase.
Unlikethe CFUcounts,toxin concentrationscontinue toincrease as
swelling increases. It remains to be determined how this dynamic
interaction occurs in human lesions, which are not at all as
circumscribed as those in the mouse. In humans, it will also be
important to determine the best sites within lesions and the best
techniques (e.g., swab or fine needle aspirate) to obtain toxin-
containing specimens.
The impact of drug treatment with RIF-STR on footpad
swelling and cultivable M. ulcerans was confirmed in these
experiments. Importantly, we also observed a reduction in
detectable mycolactone after the onset of drug treatment. In all
three cases, the observations were made on a weekly basis
providing further precision to the observations. We also found that
the all-oral alternative RIF+CLR regimen for Buruli ulcer
treatment, though possibly less bactericidal, appears to be equally
active as the standard RIF+STR regimen in reducing swelling and
blocking toxin production. Thus, the inhibition of the enzymatic
machinery involved in producing a virulence factor may be as
effective as and possibly less toxic than the killing of the bacteria.
The fluorescent TLC method could be an excellent tool for both
the rapid and early detection of M. ulcerans infection and for
monitoring the response to antimicrobial chemotherapy. The
assay is practical in that absolute ethanol is readily available in all
clinics and mycolactone is preserved in absolute EtOH at room
temperature for at least 3 weeks (data not shown). The assay
should be practical in intermediate level laboratories, thus
facilitating confirmation of diagnoses before the onset of ulceration
or soon after the onset of treatment.
Supporting Information
Figure S1 Schematic of fluorescent thin layer chroma-
tography (f-TLC) procedure with examples. Top left)
Explanation of the f-TLC method; Top right) Schematic of f-TLC
layout. Center, Stained TLC plates of mouse footpads, untreated
on left and treated (RS) on right, from top to bottom: 6, 7, and 8
weeks after infection.
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